Cagrilintide (10mg) refers to a lyophilized vial of a long-acting amylin and calcitonin receptor agonist. It is actively being investigated in clinical trials for weight management and blood sugar control. It is primarily researched in combination with GLP-1 agonists (such as semaglutide).
Key Research & Clinical Details
- Mechanism: Induces significant weight loss and reduces food intake by regulating appetite in the brain.
- Research Usage: Vials of 10 mg are generally sold as a lyophilized powder for biochemical studies, receptor pharmacology, and controlled laboratory experiments.
- Clinical Trials: In combination with semaglutide (CagriSema), trials (such as the REDEFINE 1 study) are exploring its efficacy in adults with obesity.
- Administration (Clinical Context): In human trials, therapeutic doses are typically administered via subcutaneous injection once weekly.
- Storage: Requires strict handling to maintain integrity; it is typically stored in refrigerated conditions (2-6° C) while avoiding repeated freeze-thaw cycles and light exposure.




Reviews
There are no reviews yet.